Kallikrein messenger RNA in rat arteries and veins.

Saed, G M; Carretero, Oscar A.; MacDonald, Raymond J.; Scicli, A. G.

doi:10.1161/01.res.67.2.510

Cited by 80 publications

(46 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We found evidence that mRNA for glandular kallikrein is present in an established rat vascular smooth muscle cell line 12 ; in addition, Oza et al 13 recently reported that vascular smooth muscle cells in culture release kallikrein. In preliminary work, we found that vascular kininogenase activity is still present after removal of the endothelium by collagenase treatment.…”

Section: Discussionsupporting

confidence: 50%

“…Because plasma contains glandular kallikrein, 7 -8 vascular kininogenase activity could be due to trapped plasma; however, this is unlikely, as extensive washing did not remove the kininogenase from the vessel wall. We found messenger RNA (mRNA) for glandular kallikrein in rat vascular tissue, 12 suggesting that the kininogenase activity was due to locally synthesized glandular kallikrein. We used SBTI to inhibit the possible kinin-generating activity of plasma kallikrein or trypsin-like enzymes.…”

Section: Discussionmentioning

confidence: 93%

See 1 more Smart Citation

A kallikrein-like enzyme in blood vessels of one-kidney, one clip hypertensive rats.

et al. 1990

Self Cite

View full text Add to dashboard Cite

Active and inactive kallikrein or a kallikrein-like enzyme are found in the aorta, vena cava, and tail artery and veins of the rat We studied the concentration of vascular ldninogenase in rats with one-kidney, one clip renovascular hypertension and in unilaterally nephrectomized normotensive rats. Six weeks after surgery, active and total vascular kininogenase activity (active plus trypsin-activated) was measured. Blood pressure was 212±4 mm Hg in the hypertensive rats (n=33) and 120±l mm Hg in the normotensive rats (n=32) (p<0.001). Active kininogenase was lower in the hypertensive rats; although the difference was not significant in the thoracic aorta (56±8 versus 77±15), it was highly significant in the abdominal aorta (63±13 versus 167±17, p<0.001) and tail artery (48±8 versus 197±31, p< 0.003). Total vascular kininogenase activity (active plus trypsin-activated) was lower in the hypertensive rats in all arteries examined: thoracic aorta (183±16 versus 380±38, p<0.003), abdominal aorta (565+61 versus 1,093±74, p<0.001), and tail artery (532±112 versus 1,243 ± 135, p< 0.003). Active kininogenase in the vena cava was higher in the hypertensive rats (213±56 versus 131±31); however, this difference was not statistically significant, whereas in the tail veins it was highly significant (l,803±221 versus 771 ±79, p<0.003). Total venous kininogenase activity was significantly higher in the hypertensive rats (vena cava, l,850±171 versus 998±149,p<0.01; tail vein, 4,261 ±261 versus 2,521±212, p<0.001). In conclusion, we found that in rats with one-kidney, one clip renovascular hypertension both active and total vascular kininogenase are decreased in the arteries and increased in the veins. These changes may contribute to the pathogenesis of hypertension. (Hypertension 1990;16:436-440) T he kallikrein-kinin system has been implicated in the regulation of renal function and blood pressure and in the pathogenesis of various forms of hypertension. "3 We found that kallikrein or a kallikrein-like enzyme is present in the tail arteries and veins of the rat in both active and inactive (trypsin-activated) forms. Both its molecular weight and inhibition profile were similar to glandular kallikrein. It was inhibited by aprotinin and by polyclonal and monoclonal antibodies against glandular kallikrein and was resistant to soybean trypsin inhibitor (SBTI). 4 Although the function of this vascular kininogenase is not known, it could participate in circulatory homeostasis through local generation of kinins. The present study was designed to determine whether one-kidney, one clip renovascular hypertension alters the concentration of vascular kininogenase. We measured active and total kininogenase activity in the thoracic and abdominal aorta, vena cava, and tail artery and veins of rats with onekidney, one clip renovascular hypertension and in unilaterally nephrectomized normotensive rats. MethodsMale Sprague-Dawley rats weighing 200-250 g were housed in a room under conditions of constant temperature and a 12-hour light/dark cycle; ...

show abstract

Section: Discussionsupporting

confidence: 50%

Section: Discussionmentioning

confidence: 93%

A kallikrein-like enzyme in blood vessels of one-kidney, one clip hypertensive rats.

et al. 1990

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, even though the 5′ and 3′ flanking regions are highly homologous among the various genes, their regulation and site of expression are different, suggesting that small variations in the nucleotide sequence of the 5′ region can have a significant influence on gene expression. While the kallikrein gene is expressed mainly in the submandibular gland, pancreas and kidney, we detected small amounts of kallikrein mRNA in the heart, vascular tissue, and adrenal glands on polymerase chain reaction (PCR) (189,237). Kallikrein and similar enzymes have been found in the arteries and veins (190), heart (188), brain (58), spleen (57), adrenal glands (255), and blood cells (189); they have also been observed in the pituitary gland (66,216), pancreas (84), large and small intestines (242,320), and salivary and sweat glands (106) along with their exocrine secretions.…”

Section: Introductionmentioning

confidence: 93%

“…The kallikrein-kinin system in the vasculature and regulation of local blood flow-Arteries and veins contain a kallikrein-like enzyme, and both vascular tissue and smooth muscle cells in culture contain kallikrein mRNA (190,237). Vascular smooth muscle cells in culture release both kallikrein and kininogen (200).…”

Section: The Kallikrein-kinin System In Inflammationmentioning

confidence: 99%

The Kallikrein-Kinin System as a Regulator of Cardiovascular and Renal Function

Carretero¹,

Yang²,

Rhaleb³

2005

Hypertension

View full text Add to dashboard Cite

“…We have reported that vascular tissue contains a kininogenase that has the same properties as glandular kallikrein 9 and that messenger RNA for kallikrein is present in vascular tissue and smooth muscle cells in culture. 10 Oza et al n reported that vascular smooth muscle cells in culture release both kallikrein and kininogen (kallikrein substrate). Thus, it may be that vascular kininogenase generates kinins continuously and that they are rapidly destroyed by peptidases such as EP-24.15 and ACE.…”

mentioning

confidence: 99%

Zinc metallopeptidase inhibitors. A novel antihypertensive treatment.

Carretero

Scicli

1991

Hypertension

Self Cite

View full text Add to dashboard Cite

Inhibitors of two zinc metallopeptidases, angiotensin I converting enzyme (ACE) and neutral metalloendopeptidase-24.11 (EP-24.11), are antihypertensive agents. In this issue of Hypertension, Genden and Molineaux report that yet another peptidase inhibitor, metalloendopeptidase-24.15, EC 3.4.24.15 (EP-24.15), lowers blood pressure in normotensive rats. In this editorial we discuss the possible role of kinins as common mediators of part of the vasodepressor action of these peptidase inhibitors. Genden and Molineaux report that the marked fall in blood pressure caused by the EP-24.15 inhibitor is almost abolished by a kinin receptor antagonist, supporting the hypothesis that kinins play a role in the regulation of normal blood pressure. We have confirmed that the EP-24.15 inhibitor used by these investigators lowers blood pressure. Up to now, EP-24.15 has not been implicated in in vivo metabolism of kinins. Although a number of kininases have been identified, our own previous work indicated that the metabolic pathway responsible for clearing kinins from the circulation involves the action of kininase II (angiotensin I converting enzyme) and renal peptidases. Nevertheless, the main metabolic pathway involved some other unidentified enzyme, since in these experiments disappearance of kinins from the circulation was only marginally reduced by a "cocktail" of inhibitors of ACE, EP-24.11, and carboxypeptidase N. It could be that EP-24.15 is involved in kinin metabolism. However, a number of questions need to be answered with regard to the mechanism by which the EP-24.15 inhibitor lowers blood pressure. The data obtained with the EP-24.15, NE-24.11, and ACE inhibitors suggest that potentiation of vasodilator peptides is yet another possible relevant therapeutic approach to hypertension and perhaps heart failure. (Hypertension 1991;68:366-371)

show abstract

Kallikrein messenger RNA in rat arteries and veins.

Cited by 80 publications

References 30 publications

A kallikrein-like enzyme in blood vessels of one-kidney, one clip hypertensive rats.

A kallikrein-like enzyme in blood vessels of one-kidney, one clip hypertensive rats.

The Kallikrein-Kinin System as a Regulator of Cardiovascular and Renal Function

Zinc metallopeptidase inhibitors. A novel antihypertensive treatment.

Contact Info

Product

Resources

About